News
Bimekizumab in the treatment of moderate to severe hidradenitis suppurativa – another approved indication for this biological agent
In May, the primary results of the BE HEARD I and II studies evaluating the efficacy and safety of the IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate to severe hidradenitis suppurativa (HS) in adults were published in The Lancet. This is the first publication of the results of these Phase III studies. Based on these findings, the European Medicines Agency (EMA) approved bimekizumab (which is currently approved for the treatment of plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis) for the treatment of HS…
Reducing Overall Mortality by Combining Three Antihypertensives into a Single Pill
Treating hypertension to recommended target blood pressure values often requires a combination of…
Current European Recommendations for the Treatment of Renal Colic Due to Urolithiasis
At the annual congress in Milan in 2023, new recommendations from the European Association of…
MD Šimon Kozák: In algology, nothing works miraculously overnight! It is important to seek advice from specialists
Why is it not advisable to rely on one method in pain treatment? What about patients with a mixed…
Efficacy and Safety of Fenfluramine in the Treatment of Lennox-Gastaut Syndrome – An Overview of Current Knowledge
In a recently published article, British authors summarize the current knowledge on the efficacy…
Spectrum of Mechanisms of Action of Fenfluramine in the Treatment of Rare Epilepsies
Fenfluramine (FFA) is an anticonvulsant used in the treatment of rare epilepsies such as Dravet…
Hybrid Cooperating Complexes in Osteoarthritis Treatment
Intra-articular application of corticosteroids and hyaluronic acid is part of the treatment of…
Possibilities of Cannabis Use in Tourette Syndrome Therapy
A retrospective analysis and online survey conducted at a psychiatric clinic in Hanover, Germany,…
Bimekizumab in the Treatment of Psoriatic Arthritis
Arthritis can appear in up to a third of patients with psoriasis, mostly after the onset of skin…
With Dr. Miroslav Nečas, Ph.D., on the conclusions of the recent consensus of the expert panel on the practice of biological treatment of psoriasis
This February, an expert consensus on the use of bimekizumab in the treatment of psoriasis and…